HK2 and colorectal carcinoma: Halofuginone also significantly decreases the protein expression of HK2 and GLUT1 and the production of tricarboxylic acid cycle intermediates, indicating that halofuginone inhibits the glycolysis pathway of CRC, which may be mediated by the AKT/mTORC1 signaling pathway.